Published on 25/12/2025
The Transformation of Clinical Trials in China: From CFDA to NMPA
Introduction
The transition from the China Food and Drug Administration (CFDA) to the National Medical Products Administration (NMPA) in 2018 marked a pivotal moment in the modernization of China’s clinical trial and regulatory landscape. For decades, sponsors faced long timelines, unclear requirements, and inconsistent data acceptance under the CFDA. With the NMPA, China signaled its commitment to global harmonization, efficiency, and patient safety. The reforms have shortened trial initiation timelines, expanded site accreditation, and strengthened Good Clinical Practice (GCP) enforcement. These changes not only increased China’s attractiveness for multinational clinical trials but also improved domestic innovation capacity. This article explores the impact of the CFDA-to-NMPA transition on clinical trials, detailing regulatory reforms, operational improvements, and strategic implications for sponsors.
Background and Regulatory Framework
CFDA’s Limitations
Under the CFDA, sponsors often waited two to three years for trial approvals. Limited regulatory resources and a lack of harmonization with ICH guidelines led to delays and inefficiencies. Bridging studies were frequently required, further delaying patient access to innovative therapies.
Creation of the NMPA
In 2018, the CFDA was restructured into the NMPA under the State Administration for Market Regulation. This
Case Example: Bridging Study Reform
Previously, foreign drugs often required separate Chinese bridging studies before approval. Under the NMPA, acceptance of multinational trial data has become more common, eliminating redundancies and reducing drug lag for oncology and rare disease therapies.
Core Clinical Trial Insights
IND and CTA Approvals
The introduction of the 60-day “silent approval” system under the NMPA revolutionized trial initiation timelines. While CFDA approvals could take years, the NMPA now aligns with global standards, similar to FDA and EMA review timelines. This has significantly improved China’s attractiveness for global sponsors.
Ethics Review and Oversight
The NMPA strengthened the role of ethics committees, requiring standardized processes and piloting centralized ethics reviews for multicenter trials. This addressed long-standing inconsistencies in ethical oversight under the CFDA.
Data Integrity and Inspections
The NMPA implemented risk-based GCP inspections to address historical concerns about data reliability. In 2015, a major audit revealed widespread issues, but subsequent reforms have improved data credibility, aligning China’s standards with ICH E6(R2).
Site Accreditation Reforms
One of the most significant changes was the move from a restrictive site approval model to a streamlined site filing system. This reform expanded the number of eligible hospitals and reduced trial initiation bottlenecks, addressing one of the major limitations of the CFDA era.
Accelerated Approval Pathways
The NMPA introduced Breakthrough Therapy, Priority Review, and Conditional Approval mechanisms, particularly benefiting oncology and rare disease drugs. These reforms mirror FDA and EMA expedited pathways, ensuring earlier access for Chinese patients.
Impact on CROs and Sponsors
CROs and sponsors had to adapt rapidly to new compliance requirements, inspection standards, and operational timelines. While challenging, these reforms positioned China as a competitive environment for multinational clinical development.
Best Practices & Preventive Measures
Sponsors should integrate China into global clinical development plans earlier, leveraging NMPA’s acceptance of multinational data. Early engagement with regulators through pre-IND consultations helps clarify expectations. CRO partnerships are critical for ensuring site readiness, ethics compliance, and inspection preparedness. Establishing harmonized SOPs across global and Chinese sites prevents compliance gaps.
Scientific & Regulatory Evidence
The NMPA reforms reflect alignment with ICH E6(R2) GCP, ICH E17 MRCT guidelines, and WHO GCP. Comparative evidence with FDA and EMA expedited review pathways demonstrates convergence in regulatory practices. The 2019 Drug Administration Law further reinforced pharmacovigilance and post-market safety, elevating China’s system to global standards.
Special Considerations
Despite progress, challenges remain. Ethics review fragmentation continues in some regions, and site capacity disparities between Tier-1 and Tier-2 hospitals persist. Sponsors must consider China’s data localization laws, which require domestic storage of patient data and genetic materials, impacting multinational data integration.
When Sponsors Should Seek Regulatory Advice
Sponsors should consult the NMPA when planning IND submissions, adaptive trial designs, or trials involving genetic data subject to Human Genetic Resources Administration of China (HGRAC) oversight. Pre-IND and mid-trial consultations help clarify expectations, reducing delays and compliance risks.
Case Studies
Case Study 1: Oncology Trial Under NMPA
A multinational oncology sponsor initiated a Phase III trial in 2020 using the NMPA’s silent approval system. The trial launched within 75 working days, compared to more than two years under the CFDA. This accelerated access demonstrated the impact of NMPA reforms on trial speed.
Case Study 2: CRO Adaptation to NMPA Oversight
A local CRO faced increased scrutiny during an NMPA inspection for data integrity. By implementing electronic data capture (EDC) systems and expanding staff training, the CRO achieved compliance and secured more multinational contracts, reflecting how reforms drive higher quality standards.
FAQs
1. Why was the CFDA replaced by the NMPA?
The transition aimed to modernize China’s regulatory system, centralize oversight, and align with international best practices.
2. How did the NMPA change trial approval timelines?
The NMPA introduced a 60-day silent approval system, reducing approval times from years to months, aligning with FDA and EMA benchmarks.
3. Are bridging studies still required in China?
Not always. If multinational data includes adequate Chinese patient representation, the NMPA may waive bridging studies.
4. How did ethics oversight improve under the NMPA?
The NMPA strengthened ethics committees and piloted centralized reviews, improving consistency compared to CFDA-era practices.
5. What impact did reforms have on CROs?
CROs faced higher compliance expectations but gained more opportunities as sponsors expanded trial activity in China.
6. Which therapeutic areas benefit most from NMPA reforms?
Oncology, rare diseases, and vaccines benefit most due to accelerated review pathways and greater data acceptance.
Conclusion & Call-to-Action
The transition from CFDA to NMPA fundamentally reshaped China’s clinical trial environment. By reducing timelines, improving ethics oversight, and expanding site accreditation, the reforms positioned China as a global leader in clinical research. For sponsors, these changes offer opportunities but demand strict compliance and proactive regulatory engagement. Organizations planning clinical trials in China should integrate NMPA strategies into global development plans, partner with experienced CROs, and invest in site capacity building to fully leverage China’s evolving regulatory landscape.